Latest industrial biotechnology Stories
SAN DIEGO, March 5, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it is notifying holders of the $34,851,000 outstanding principal amount of its 5.5% Convertible Senior Notes due 2027 that it will repurchase at each holder's option on April 2, 2012 all or a portion of such holder's notes at a price equal to $1,000 per $1,000...
SAN DIEGO, March 5, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported financial results for the fourth quarter and year ended December 31, 2011. "2011 was an important year for Verenium. The growth in our product and collaborative revenues further validates the strength of our technology platform and our ability to create superior products and...
Applying 21st century tools and technologies to manage land use, maximize biomass production, and increase the efficiency of processes for extracting energy from renewable resources will enable the biofuels industry to overcome current challenges in bioenergy production, according to a comprehensive review article published in Industrial Biotechnology, a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com). The article is available free online at...
SAN DIEGO, Nov. 10, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the third quarter and nine months ended September 30, 2011. "We have made strong financial and operational progress in the first nine months of this year," said James E. Levine, President and Chief Executive Officer...
BioCee, a Minnesota-based material science and industrial biotechnology company, announced today that it has signed an asset purchase and license agreement to access certain technology from Verenium Corporation, a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, for the development of an environmentally-friendly biological method of removing sulfur from oil and oil distillates Minneapolis, Minnesota (PRWEB) October 05,...
SOUTH SAN FRANCISCO, Calif., Oct. 5, 2011 /PRNewswire/ -- A recent survey of California's pioneering industrial biotechnology sector shows that this sector has great potential for job growth in the state. California's industrial biotechnology industry increased employment by 632 percent in the past five years, according to a survey conducted by BayBio and BIOCOM, the leading biotechnology industry associations in the state, and Radford, a compensation consulting firm. California's...
SAN DIEGO, Aug. 9, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the second quarter and six months ended June 30, 2011. "I am very pleased with the progress we've made in terms of product revenues and partnership negotiations in the first half of the year," said James E. Levine,...
WASHINGTON, June 27, 2011 /PRNewswire/ -- With a 150 year expertise in the genetic improvement of animals and plants, world-class research institutions, and a globally focused outlook, New Zealand's biotech industry is well positioned as a source of innovative science, technologies and products. Led by industry organization NZBIO and New Zealand Trade and Enterprise, more than 26 New Zealand companies are showcasing their capabilities in human health care, animal husbandry, plant and food...
SAN DIEGO, May 12, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the first quarter ended March 31, 2011. "I am pleased with the operational and financial progress made in the first quarter," said James E. Levine, President and Chief Executive Officer at Verenium. "Product revenues...
JUPITER, Fla., May 9, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced that Jan Wery, Ph.D., Science Director of Dyadic's research and development center in The Netherlands, will be making a presentation entitled, Efficient Saccharification of...
